Evidence map›Paper›PMID 35693402›Full record

ArticleHepatobiliary surgery and nutrition2022

Impact of living donor liver with steatosis and idiopathic portal inflammation on clinical outcomes in pediatric liver transplantation: Beijing experience.

Xinyan Zhao, Yafei He, Jimin Liu, Qian Zhang, Liwei Liu, Wei Qu, Ying Liu, Zhigui Zeng, Haiming Zhang, Jidong Jia and 3 more

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Hepatobiliary surgery and nutrition, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.4field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 12 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

13 authors at 4 institutions in 2 countries.

Xinyan ZhaoLiver Research Center, Beijing Friendship Hospital, Capital Medical University, Beijing, China.
Yafei He *Liver Transplant Center, Beijing Friendship Hospital, Capital Medical University, Beijing, China.
Jimin LiuDepartment of Pathology and Molecular Medicine, Faculty of Health Sciences, McMaster University, Hamilton, ON, Canada.
Qian ZhangClinical Center for Pediatric Liver Transplantation, Capital Medical University, Beijing, China.
Liwei LiuLiver Research Center, Beijing Friendship Hospital, Capital Medical University, Beijing, China.
Wei QuLiver Transplant Center, Beijing Friendship Hospital, Capital Medical University, Beijing, China.
Ying LiuLiver Transplant Center, Beijing Friendship Hospital, Capital Medical University, Beijing, China.
Zhigui ZengLiver Transplant Center, Beijing Friendship Hospital, Capital Medical University, Beijing, China.
Haiming ZhangLiver Transplant Center, Beijing Friendship Hospital, Capital Medical University, Beijing, China.
Jidong JiaLiver Research Center, Beijing Friendship Hospital, Capital Medical University, Beijing, China.
Liying SunLiver Transplant Center, Beijing Friendship Hospital, Capital Medical University, Beijing, China.
Lin WeiLiver Transplant Center, Beijing Friendship Hospital, Capital Medical University, Beijing, China.
Zhijun ZhuLiver Transplant Center, Beijing Friendship Hospital, Capital Medical University, Beijing, China.
Beijing Friendship Hospital · CNCapital Medical University · CNNational Clinical Research Center for Digestive Diseases · CNMcMaster University · CA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: To evaluate the impact of steatosis and/or idiopathic portal inflammation (IPI) in living donor livers on recipients' clinical outcomes. Methods: We assessed 305 qualified donor liver samples from June 2013 to December 2018. Donors and recipients' clinical characteristics, including follow-up data were retrieved. The graft and overall survival with/without steatosis or portal inflammation were compared by Kaplan-Meier analysis. Results: For living donors, the medium age of was 31.2 (28, 35.8) years old; liver histopathology showed macrovesicular steatosis: 0-5% 264/305 (86.6%) and 5-30% 41/305 (13.4%), IPI: no 220/305 (72.1%) and mild 85/305 (27.9%). For recipients, the medium age was 1.0 (0.6, 1.5) years old; the median pediatric-end-stage-liver-disease score was 16 (5.0, 26.0) and medium follow-up time was 32.8 (24.8, 52.0) months. Biliary atresia (69.5%) was the main indication for liver transplantation (LT). Conclusions: The presence of steatosis and portal inflammation of the donor liver did not impact the clinical outcomes including transaminase or bilirubin normalization, short-/long-term complications and recipients' survival. However, recipients with high pediatric-end-stage-liver-disease score (>16) receiving donor liver with portal inflammation, but not steatosis, had trend negative effect on recipients' survival. In conclusion, donor livers with mild steatosis and portal inflammation were qualified for pediatric living donor LT. However, donor liver with mild portal inflammation would better not be allocated to recipients with high pediatric-end-stage-liver-disease score. This study provided new evidence in pediatric living donor liver allocation.

Indexed as

Graft/overall survivalidiopathic portal inflammation (IPI)nonalcoholic fatty liver disease (NAFLD)pediatric living donor liver transplantation (LT)steatosis

Identifiers

PMID35693402
PMCPMC9186188
OpenAlexW3159462258

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.